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1. Introduction 
Sleep has been identified as an essential human need; this is partly because of the metabolic 
activities that occur while the individual is sleeping. Normal sleep is divided into non–rapid 
eye movement (NREM) and rapid eye movement (REM) sleep. NREM sleep comprises 75% 
to 80% of total sleep time (TST), and is characterized by relatively quiescent brain activity 
and decreased metabolic rate (Carskadon & Dement, 2000). NREM sleep consists of four 
stages (S1-S4), with each stage leading to a progressively deeper sleep. REM sleep follows 
slow wave sleep (SWS), or deep sleep, and increases over the night, comprising 20% to 25% 
of TST. REM sleep is characterized by an activated EEG pattern, muscle atonia, and episodic 
bursts of rapid eye movements. Normal sleep provides a period of physiologic and mental 
rest. During sleep, sympathetic tone decreases and parasympathetic tone increases, leading 
to a reduction in heart rate, arterial blood pressure, and cardiac output (Rosenthal, 1998). 
Deep sleep is theorized to be necessary for physiologic restoration. REM sleep is associated 
with dreaming, and is essential for maintaining emotional and cognitive well-being (Redline 
et al., 2004).   
Waking and consciousness depend on the activity, of neurons in the ascending reticular 
activating system of the brainstem. These neurons project into the thalamus, hypothalamus 
and basal forebrain and eventually send projections to the cortex. There are particular 
neurotransmitters, such as the catecholamines, acetylcholine, histamine, glutamate and 
aspartate, that are localized within the reticular formation and have important roles in 
cortical activation and arousal (Jones, 1989). Sleep-promoting neurotransmitters include 
gamma aminobutyric acid (GABA), adenosine, and melatonin. Specific stages of sleep are 
regulated by the turning “on” and “off” of various neurons. REM “on” cells use GABA, 
acetylcholine, and glutamine, whereas REM “off” cells use norepinephrine and serotonin." 
REM On cells" are cholinergic cells in the lateral pontine and medial medullary reticular 
areas that innervate the thalamus, hippocampus and hypothalamus. These cells discharge at 
high rates during REM and show little or no activity during NREM."REM Off cells" are 
noradrenergic and serotonergic cells found in the locus coeruleus and raphe. These are cells 
which are slow or silent during REM sleep. Affecting levels of norepinephirne or serotonin 
can have an effect on REM sleep (Hoyt, 2005).  
Sleep regulation is a balance between a homeostatic sleep need and an intrinsic body clock, 
or circadian pacemaker. Located in the suprachiasmic nucleus, the circadian pacemaker 
determines the onset and termination of sleep, and is partially regulated by environmental 
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cues such as light and ambient temperature (Rosenthal, 1998). Melatonin, a physiologic 
sleep promoter, is inhibited by ambient light, and its circulation is decreased during 
daylight hours. The adrenal secretion of cortisol, which is associated with wakefulness, 
follows a circadian pattern. Regulated by the hypothalamic-pituitary axis, cortisol levels 
peak in the early morning hours in preparation for the increased metabolic demands during 
wakefulness (Mahowald, & Schenk, 1989). 
Some medical illnesses, such as congestive heart failure (CHF), diabetes mellitus, chronic 
obstructive pulmonary disease and renal disease, can directly impair sleep physiology, 
leading to a cyclical interaction (Ballard, 2005).  End-stage renal disease (ESRD) is one of 
these diseases. Approximately 50% of patients with chronic end-stage renal disease 
undergoing hemodialysis (HD) have insomnia and other sleep disorders (Hanly, 2007). 
Patients often complain of restless leg syndrome (RLS), periodic limb movement disorder 
(PLMD), bone pain, nausea, and pruritus (Merlino et al., 2006). The etiology of sleep 
disorders appears to be related to metabolic derangements associated with ESRD or from 
coexisting diabetes mellitus (Ballard, 2005). 
2. Sleep problems in hemodialysis patients 
Sleep complaints and sleep disorders are common in patients with end-stage renal disease. 
Although variable, their prevalence has been reported to be higher when compared to the 
general population (Merlino et al., 2006). The experiences of sleep alteration in ESRD 
patients have been studied. Interestingly, 80% of hemodialysis patients suffer from sleep 
abnormalities and the prevalence is higher than that in the general population (Gul et al., 
2006). Holley et al. (1992) surveyed 70 dialysis patients, and reported sleep disturbance 
experienced mainly included trouble falling asleep (67%), nighttime waking (80%), early 
morning waking (72%), restless legs (83%), and jerking legs (28%). However, Walker et al. 
(1995) found daytime sleepiness was the most commonly reported problem (66.7%) 
followed by restless legs syndrome (57.4%).  Generally, the most prominent sleep disorders 
among hemodialysis patients are sleep apnea syndrome, restless leg syndrome, periodic 
limb movement disorders, and insomnia (De Santo et al., 2005; Holley et al., 1992; Sabry et 
al., 2010). 
2.1 Sleep apnea syndrome 
The prevalence of sleep apnea syndrome in hemodialysis patients is at least 10 times higher 
(Kraus & Hamburger, 1997) than those values reported in the general population (Young et 
al., 1993). In another recent investigation, an apnea/hypopnea index higher than 5 was 
found in 31% of the (young) non-diabetic HD patients studied (Rodriquez et al, 2005). 
Sleep apnea syndrome (SAS) is a major clinical disturbance defined as an intermittent 
interruption of air flow at the level of nose and mouth during sleep. These abnormalities 
cause frequent decreases in O2 saturation and awakenings. Episodes of apnea are considered 
clinically significant if they persist for more than 10 s; however, apnea episodes may last up 
to 2 min. SAS is the clinical consequence of frequent (at least 10 events per hour) episodes of 
apnea during sleep (Tatomir et al., 2007). There are three major types of sleep apnea: 
obstructive sleep apnea (OSA), the central type (CSA), and the mixed type, which includes 
features of both obstructive and central apnea. OSA is characterized by obstruction of the air 
flow determined by the occlusion of the oropharyngeal tract (Zoccali et al., 2001).  
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OSA occurs when the patient no longer has airflow but there is respiratory effort. CSA is 
determined by the transient abolition of nerve conduction to the respiratory muscles. 
Central apnea is defined when the patient has both cessation of airflow and the lack of 
respiratory effort followed by spontaneous resumption of breathing. Mixed apnea is the 
combination of central and obstructive apneas. All of these conditions can cause arterial 
oxygen desaturation and they may even be present in the same person (Tatomir et al., 2007; 
Zoccali et al., 2001). Researchers have speculated that the chronic metabolic acidosis suffered 
by patients with hemodialysis causes these sleep disorders; as the body attempts to correct 
the acidosis, the patient exhales more carbon dioxide and the hypocapnia that results may 
be inadequate to fuel respiration (Kimmel, 1989). Another theory is that these patients 
frequently have peripheral neuropathy, either from the ESRD or diabetes mellitus, and if the 
neuropathy affects the nerves innervating the upper airway, then SAS will occur (Fletcher, 
1993). There is also evidence that SAS is associated with increased morbidity, and mortality, 
as the patient with ESRD who suffers with SAS is looking at a future with probable 
pulmonary hypertension and right heart failure, as well as a shortened lifespan (Fletcher, 
1993; Parker, 1997). While, there are no ready answers for the causes of these sleep disorders 
seen in patients with ESRD undergoing HD, it is crucial that the health care provider be 
aware of the syndrome. 
The awareness of SAS as a potent cardiovascular risk factor in ESRD undergoing HD has 
generated new enthusiasm in examining novel therapeutic strategies to modify sleep apnea 
in the patient population. To date, conservative non-pharmacological treatments (e.g. 
weight loss and avoidance of potentiating medications) have yielded limited success. Nasal 
continuous positive airway pressure therapy remains a mainstay of treatment of SAS in the 
non-ESRD population. Continuous positive airway pressure involves a mask fitting over the 
nose or mouth in which positive pressure is administered to the airway keeping the upper 
airway patent during sleep. In the general population, the treatment of sleep apnea with 
continuous positive airway pressure improves quality of life ( D'Ambrosio et al.,1999), 
vigilance, cognition, sexual performance, and normalizes nocturnal blood pressure profile 
(Faccenda et al., 2001).  In the HD population, continuous positive airway pressure was used 
in a small study of eight patients with some improvement in nocturnal oxygenation, and 
five of six patients reporting improved daytime alertness (Pressman, 1993). Finally, given 
the contribution of uremia in the pathogenesis of SAS in ESRD, attempts in optimizing 
uremia control in the forms of nocturnal hemodialysis (NHD) and renal transplantation 
have shown early clinical success (Auckley et al, 1999;Hanly & Pierratos, 2001). It is 
tempting to speculate that similar to those with refractory hypertension, the treatment of 
sleep apnea in the HD population would improve their quality of life, augment 
rehabilitation, and perhaps impact on the poor survival of patients. 
2.2 Restless Legs Syndrome  
Restless Legs Syndrome (RLS) is a neurological movement disorder that is common, under-
diagnosed, under-treated, and has a poorly understood etiology (Patrick,2007). Restless legs 
syndrome (RLS) is a sensorimotor movement disorder characterized by the irresistible need 
to move associated with feelings of discomfort and parasthesias (International Restless Legs 
Syndrome Study Group, 2003). The incidence of idiopathic RLS (iRLS) varies between 5–
15% in the general population (Nicholas et al., 2003). In the HD population, the prevalence 
of secondary RLS may be greater, reported to be between 6–62% (Takaki et al., 2003;Unruh 
et al.,2004) with some geographic variability (Kavanagh et al., 2004). With employment of 
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standardized criteria by IRLSSG, this decreased to 12–48% (Siddiqui  et al.,2005; Takaki et al, 
2003;Unruh et al., 2004).  RLS is observed more commonly in women than men, more 
commonly with increasing age and with co-morbid diabetes. Other potential correlates of 
RLS include lower socio-economic status, worse somatic and mental health and diabetes 
(Berger et al., 2004; Siddiqui  et al.,2005). A high correlation between RLS and PLMS has also 
been noted (Allen et al. 2003, Liao et al.,2008). 
The pathophysiology of RLS in uremia remains unknown however, several theories have 
been proposed. Potential risk factors include anemia, iron deficiency, dialysis vintage, 
calcium/phosphate imbalance, and peripheral and central nervous system 
abnormalities(Berger et al., 2004;Unruh et al.,2004).  
Evidence for a possible relationship of iron deficiency to RLS in this patient population has 
been explained by the universal occurrence of anemia, which is commonly acquired in 
patients with end-stage renal disease due to inadequate production of erythropoietin (Gigli 
et al.,2004). Anemia in ESRD is associated with several co-morbid conditions, including 
congestive heart failure, stroke, cognitive dysfunction, left ventricular hypertrophy,and 
worsening iron deficiency due to loss from hemodialysis (Allen,2004; Gigli et al.,2004) 
Ferritin levels under 100 ng/mL reflect depletion of iron stores and complicate the treatment 
of anemia in patients on dialysis (Easom, 2006; Patrick ,2007) 
Multiple causes of secondary RLS including iron deficiency anemia, diabetes mellitus, 
Parkinsons disease, pregnancy, rheumatic disease, venous insufficiency and less commonly in 
association with peripheral neuropathies, vitamin deficiencies, lumbosacral radiculopathy, 
spinal stenosis, excess caffeine intake, administration of some tricyclic antidepressants, 
hypoglycemia and hypothyroidism (Nichols et al.,2003;  Siddiqui  et al.,2005;Unruh et al.,2004). 
The revised IRLSSG criteria (Allen et al. 2003) for RLS included four essential diagnostic 
criteria additional supportive features. The criteria include unpleasant and uncomfortable 
sensations associated with an urge to move the limbs with symptoms worsened by rest, 
relieved by activity and typically worse toward the evening. Positive family history, initial 
therapeutic response to L-dopa or a dopamine-receptor agonist are supportive evidence. At 
least 85% of patients with RLS may also have concomitant periodic limb movements (PLMS) 
though this may be the result of other disorders such as obstructive sleep apnea. 
Treatment of ESRD-associated anemia with erythropoietin has been shown to decrease 
arousal due to PLMS and produce trends toward higher sleep quality (Benz et al 2000). As 
will be reviewed later, intravenous (I.V.) iron in ESRD patients has been shown to be highly 
effective in causing remission of RLS symptoms (Sloand et al., 2004). 
Given that alterations of the dopaminergic pathways may contribute to the development of 
RLS in ESRD, pharmacological treatment of RLS with Levodopa (L-DOPA) has been studied 
and was shown to improve sleep and reduce nocturnal limb movements in three 
prospective trials (Sandyk et al.1987; Trenkwalder et al., 1995; Walker, 1996). Recently, 
treatment with pergolide, a dopamine agonist was also examined in a double-blind placebo-
controlled crossover study in ESRD patients (Pieta et al., 1998).  In contrast to the use of L-
DOPA, pergolide resulted in decreased symptoms without objective improvements in 
nocturnal limb movement or sleep architecture. Limited beneficial data regarding the use of 
other dopamine agonists have also been reported (Miranda et AL., 2004; Pellecchia et al., 
2004). Folate is also involved in the production of dopamine in the CNS. Folate, as 5-
methyltetrahydrofolate, increases production of CNS tetrahydrobiopterin, a cofactor in 
tyrosine hydroxylase production  significant reduction in RLS symptoms and decreased leg 
movements during sleep (p=0.018). With the exception of this one trial, there is only limited 
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information from case reports of significant symptom reduction in pediatric RLS using 
dopaminergic agents (Konofal et al.,2005) 
2.3 Periodic Limb Movement Disorder  
Periodic limb movement disorder (PLMD) is a condition characterized by periodic episodes 
of repetitive and highly stereotyped limb movements that occur either during sleep (PLMS) 
or in wakefulness (PLMW) (Walker et al., 1995). This syndrome is more often seen in the 
patient with ESRD than in the general population (Pressman et al., 1995). The presence of 
PLMS is responsible for sleep problems in up to 72% of patients with ESRD (Benz et al., 
2000) and the presence of PLMS is a more accurate predictor of mortality than coexisting 
diseases, serum albumin, or urea reduction ratio (Winkelman et al., 1996). A high correlation 
between RLS and PLMS has also been noted (Allen et al. 2003). 
Treatments with high-dose iron dextran and normalization of hematocrit with recombinant 
human erythropoietin have been demonstrated to improve RLPLMD in ESRD patients 
(Benz et al, 1999; Sloand et al., 2004). Alterations in dopamine and opioid synthesis may also 
play a role in the high prevalence of RLS and PLMD in uremia; however, data are limited. 
Indirect evidence stems from the notion that treatment with dopamine agonists, dopamine 
precursors in ESRD patients may improve RLS and PLMD symptoms (Sandyk et al.1987; 
Trenkwalder et al., 1995; Walker, 1996).  
2.4 Insomnia 
Insomnia is defined as a disorder of difficulty initiating sleep (DIS), difficulty maintaining 
sleep (DMS), and/or early morning awakening (EMA). Insomnia is commonly defined as 
the subjective sensation of short, unsatisfying sleep, despite the ability to sleep (Sabbatini et 
al., 2002). It may be secondary either to trouble falling asleep and/or to night‐time waking, 
which must be persistently present (i.e. three to four times a week for several weeks) ( Leger 
et al.,2002). The prevalence estimates of insomnia vary because of differences in definition, 
diagnosis, population characteristics, and research methodologies. Insomnia is a common 
sleep problem, however, and its prevalence in the general population ranges from 4% to 
64% (Terzano et al., 2004; Chesson et al., 2000).  The prevalence of insomnia is substantially 
greater in dialysis patients and has been reported to range from 45% to 59% (İliescu et al., 
2003; İliescu et al., 2004; Sabbatini et al., 2002).  
Insomnia is characterized by one or more of the following symptoms: difficulty falling asleep 
("sleep onset insomnia"), difficulty staying asleep ("sleep maintenance insomnia"), early 
awakening or poor sleep quality ("non-restorative sleep") (Ohayon et al., 2002; Meyer, 1998). 
Insomnia is primarily a clinical diagnosis and it is most frequently diagnosed from data 
obtained from the history and from sleep diaries. PSG is not indicated in the initial evaluation 
of insomnia but may be necessary in chronic treatment-resistant cases and in patients in whom 
specific sleep disorders (SASRLSPLMS) are suspected (Bonner et al., 2008).  
Insomnia may be caused by a variety of reasons, with the most frequent causes listed by 
researchers as: restless legs syndrome (RLS), periodic leg movements during sleep (PLMS), 
sleep apnea syndrome (SAS) and depression (Kimmel, 1989; Parker, 1997; Welch & Austin, 
2001). The prevalence of insomnia due to RLS in dialysis patients ranges from 57% to 83% ( 
Holley et al., 1992; Sabbatini et al., 2002; Walker et al., 1995). Elderly patients, those with longer 
dialysis durations, dialysis shift, and those with high levels of parathyroid hormone (PTH) or 
diabetes mellitus are at higher risk of insomnia; however, the dialysis type and biochemical 
parameters are not important determinants of insomnia (Han et al., 2002; Sabbatini et al., 2002).  
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Most studies assessing the effectiveness of different treatment modalities in insomniacs 
address short-term treatment of insomnia (Montgomery &Dennis., 2004; Morgan et al., 2003; 
Smith et al., 2002). Extra care and caution has to be exercised when treating insomnia in 
patients with renal impairment. Most hypnotics should be administered in appropriately 
reduced doses and interactions with the numerous medications used in the different HD 
populations should be considered carefully when prescribing a hypnotic to patients with 
renal failure (Novak et al., 2006). Surprisingly there is an almost complete lack of 
pharmacologic studies in renal patients suffering from insomnia. In a small randomized 
study using the PSQI Sabbatini et al. (2003). suggested that zaleplon improved sleep efficacy 
in maintenance hemodialysis patients. 
Nonpharmacologic interventions include sleep hygiene measures relaxation therapy and 
biofeedback stimulus control therapy sleep restriction and cognitive behavioral therapy 
(Montgomery &Dennis., 2004; Morgan et al., 2003). These interventions have been shown to 
be beneficial in the long-term management of patients with chronic hypnotic use. Cognitive 
behavioral therapy for insomnia in the routine general practice setting improved sleep 
quality reduced hypnotic drug use and improved health-related quality of life at a favorable 
cost in chronic insomniacs. 
3.  Related factors with sleep problems in hemodialysis patients 
A multitude of causes including anemia, blood urea levels, plasma creatinine levels, 
parathyroid hormone (PTH) concentrations, increased blood pressure, quality of life, and 
illness intrusiveness may contribute to sleep disturbances in patients on maintenance 
hemodialysis (Hanly et al., 2003; Iliescu et al., 2004; Sabbatini et al.,2003). Furthermore, there 
is a positive correlation between sleep disturbances and increased morbidity and mortality 
related to cardiovascular disease and infectious  complications, the 2 major causes of death 
in hemodialysis patients (De Santo et al., 2005). Sleep disorders in hemodialysis patients is a 
multifactorial complaint, stemming from Uremic toxins and dialysis procedure, other 
medical problems, psychiatric or psychosocial background. 
3.1 Uremic toxins 
Several studies in the past 30 years have shown that uremic patients are at great risk for 
disordered sleep. A study by Millman et al. (1985) noticed a slight but significant 
relationship between sleep apnea syndrome and azotemia. In a recent prospective study of 
incident HD patients followed-up for 1 year, higher dialysis efficiency was associated with 
fewer sleep disturbances (Unruh et al., 2006). These latter data are further supported by the 
results of Hanly et al. (2001), who studied patients on conventional hemodialysis (4 h three 
times a week) who then switched to nocturnal (intensive) dialysis (8 h for 6 or 
7 days/week). A spectacular correction of sleep apnea was recorded in this small-scale 
study (Hanly et al., 2001). Finally, the impact of uremic toxins is highlighted by the fact that 
sleep disorders are more frequent and more severe in dialyzed patients compared with 
subjects with pre-dialysis CKD (Merlino et al., 2006).  
3.2 Interdialytic weight gain and hypertension 
Excessive interdialytic weight gain has been associated with poor compliance and high 
blood pressure (Rahman et al., 2000). While the mechanism of the association between 
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interdialytic weight gain and sleep problems is unclear, we speculate that large interdialytic 
weight gains result in expanded intravascular volume, which has been associated with 
upper airway obstruction (Chiu et al., 2006).  
The length of sleep during the night before a hemodialysis session after a long interdialytic 
interval (3 days, the “weekend interval”) is significantly shorter compared to the usual sleep 
length following a short interdialytic interval. This led to some speculation regarding the 
possible effect of interdialytic weight gain (IWG) on sleep (Bertini et al., 1999). Furthermore, 
patients with uncontrolled pre-dialysis systolic pressure (usually a sign of hypervolemia in 
these patients) experience clinically overt insomnia more frequently (De Santo et al., 2001); 
in patients with chronic diseases, systolic hypertension appears to be a cause of sleep 
disturbances (Katz & McHorney 1998; Sabbatini et al., 2002; Thase, 2005). 
3.3 Dialysis shift 
The dialysis shift has several effects on patients with ESRD.  Morning-shift HD patients 
experience more insomnia (Sabbatini et al., 2002), but also have longer survival times 
(Bliwise., 2001)  than patients on other dialysis shifts. In according to another study (Merlino 
et al., 2006), for patients undergoing HD in the morning shift, the risk of subclinical 
insomnia is up to 18 times higher than for those who have their dialysis session in the 
afternoon.  However, morning-shift HD patients have higher intradialytic sleepiness, which 
is associated with more decreased body temperature during HD, than patients on other 
dialysis shifts (Parker et al., 2003). 
3.4 Dialysis vintage 
The longer the dialysis vintage, the more significant is the prevalence of sleep quality 
disorders (Veiga et al., 1997).   In a study by De Santo et al., (2005), patients with subclinical 
or clinical sleep disorders had double the dialysis vintage of those without sleep complaints; 
in patients with a medium dialytic age of 75 months, the prevalence of sleep disorders is 
close to 80%. These data are not surprising, taking into account the accumulation of 
comorbidites, including peripheral neuropathy and CVD, whilst on dialysis on long-term. In 
a polysomnographic study by Tatomir et al.,(2007)  in patients hemodialyzed for more than 
10 years, all patients has disturbed sleep with frequent awakening and reduced sleep 
efficiency. One-half of these patients had sleep-related breathing disorders, i.e. sleep apnea 
syndrome. 
3.5 Restless legs syndrome 
Restless legs syndrome (RLS) usually becomes apparent during resting and may 
significantly interfere with sleep.  An association between RLS and insomnia in patients on 
maintenance hemodialysis has been suggested already by a few papers (Musci et al., 2005; 
Sabbatini et al., 2002; Walker et al., 1995). Moreover, RLS is associated with a low quality of 
sleep and lower quality of life.  
3.6 Other medical factors  
Other medical factors include the pain and discomfort caused by illnesses such as arthritis, 
cardiovascular disease, chronic obstructive pulmonary disease (COPD), cerebrovascular 
disease, neurological disorders, asthma, headaches, and more.  The prognosis of patients 
with chronic uremia is influenced by the presence of comorbidities, mainly by 
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cardiovascular disease (CVD), which causes roughly 50% of deaths (Covic et al., 2006).  A 
study by Mucsi et al. (2004), demonstrated that comorbidities are independent predictors of 
sleep disturbances in patients on maintenance dialysis. According to another study, the 
average Charlson Comorbidity Index (CCI) in patients without sleep disorders was 4.10, 
while scores in patients with subclinical and clinically overt sleep disorders were 6.10 and 
6.81, respectively (De Santo et al.,2005). This highly significant association in the Italian HD 
population was maintained regardless of age. To conclude so far, any in-depth research on 
the quality of sleep in renal patients must consider the magnitude of comorbidities.  
3.7 Age 
Sleep difficulties are closely correlated with older age in patients with chronic uremia 
(Iliescu et al., 2003). Yoshioka et al.(1993) found that advanced age and long-term dialysis 
therapy directly affected patients experiencing sleep problems. The disorders are similar to 
those described in the general population, where the prevalence and severity of sleep 
disorders are also associated with old age. Each decade of age increases the risk of insomnia 
by 239%, and the risk of overt clinical insomnia by 51% (De Santo et al., 2005). Mollaoğlu 
(2004) reported a negative correlation between age and sleep quality, with sleep quality 
decreasing with advanced age in their study of 105 HD patients. In addition, community-
based studies have shown that sleep quality could be deteriorated in elderly patients due to 
increased frequency of physical diseases, multiple drug use, primary sleep disturbances, or 
lifestyle modifications (Brandenberger et al., 2003; Kamel & Gammack 2006).  
3.8 Depression 
The psychiatric condition most commonly causing sleep disorders is depression that may 
affect up to 50% of this patient population (Covic et al., 2006). The relationship between 
depression and sleep disorders is well known both in the general population and in patients 
undergoing hemodialysis (İliescu et al.,2003). Depression can be a cause, as well as a result, of 
insomnia. Dialysis patients with a Pittsburg Quality Index Sleep score of >5 (patients with a 
“difficult sleep”) have a prevalence of overt depression of 20%, while among ESRD patients 
reporting a normal sleep, the prevalence of depression is almost nil (İliescu et al.,2003).  
3.9 Medications and other substances 
Medications and other substances which may cause insomnia include beta-blockers, 
bronchodilators, corticosteroids, CNS stimulants, Tagamet, cardiovascular drugs, 
neurological drugs, alcohol, caffeine and nicotine (Merlino et al., 2006; Rosenthal, 1998; 
Unruh et al., 2006). Most prescribed as well as over-the-counter medications produce side 
effects which are either sedating or stimulating.  Drugs which cause daytime sleepiness 
include analgesics, benzodiazepines and antihistamines (Rosenthal, 1998; Unruh et al., 
2006). According to recent investigations, the use of hypnotic medication in dialysis patients 
is rather modest: 8–10% (De Santo et al., 2005; De Santo et al., 2001). In a large study, the 
reported use of sleep-inducing medication was even lower—3.6% (Merlino et al., 2006). 
However, dialysis patients with severe sleep disorders use specific medication more 
frequently (24%) (De Santo et al., 2005). Improved hemodialysis techniques, socio-
economical disparities in the studied populations, and reluctance by nephrologists to 
prescribe psychotropic medication may explain these disparities. However, we must be 
aware that chronic auto-administration of hypnotic medication may be more frequent in 
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ESRD patients compared to the general population. Moreover, according to recent data from 
the CHOICE incident dialysis population, use of benziodiazepines is associated with altered 
sleep quality during the first year of dialysis. Although this study was unable to distinguish 
between cause and effect, more effective dialysis and cognitive behavioral therapy have 
been suggested in patients with sleep disorders in need of sleep-inducing medication 
(Unruh et al., 2006). Moreover, many antidepressants actually cause paradoxical 
restlessness, therefore systematic administration of these drugs should be subjected to close 
clinical follow-up, which should be easy to accomplish in hemodialysis patients. 
Alcohol is widely used as a sleep aid. Although it does shorten sleep latency, it also causes 
sleep fragmentation, decreased REM, REM rebound and early morning awakenings. The use 
of alcohol combined with hypnotics may exacerbate sleep difficulties even more (Rosenthal, 
1998). Alcohol and (particularly) tobacco abuse is highly associated with increased 
prevalence of sleep disorders in ESRD (Merlino et al., 2006). Caffeine and other stimulants 
such as nicotine have been shown to increase sleep latency and sleep fragmentation, and to 
decrease total sleep time (Rosenthal, 1998).  Current smoking is also related with decreases 
in sleep quality during the first year of dialysis therapy in incident patients (Unruh et al., 
2006). Caffeine intake appears to have no significant impact on insomnia in ESRD (Sabbatini 
et al., 2002).  
4. Sleep quality and evaluation of sleep in hemodialysis patients 
Sleep quality is an important clinical construct for two major reasons. First, complaints 
about sleep quality are common; epidemiological surveys indicate that 15-35 % of the adult 
population complain of frequent sleep quality disturbance, such as difficulty falling asleep 
or difficulty maintaining sleep. Second, poor sleep quality can be an important symptom of 
many sleep and medical disorders (Buysse et al., 1989). 
Sleep quality” is sometimes used to refer to a collection of sleep measures including total 
sleep time (TST), sleep onset latency (SOL), degree of fragmentation, total wake time, sleep 
efficiency, and sometimes sleep disruptive events such as spontaneous arousals or apnea. 
The widely employed Pittsburgh Sleep Quality Index (PSQI), for example, provides a 
measure of global sleep quality based on a respondent’s retrospective appraisal (past 
month) of an array of sleep measures, including sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction (Krystal 
& Edinger, 2008). Sleep quality is also sometimes inferred from a collection of objective 
indices taken from polysomnography (PSG).  PSG is the most valid and accurate way to 
assess sleep.  Measures derived from PSG include: (a) total sleep time, (b) sleep efficiency 
(ratio of time spent asleep/time in bed), (c) sleep latency (time to fall asleep after lights out), 
(d) amount of wake time during sleep periods (waking after sleep onset, WASO), (e) 
number of awakenings, and (f) amount of each sleep stage ( Landis al., 2002). 
Among these objective indices are measures such as sleep onset latency, total sleep time, 
wake time after sleep onset, sleep efficiency, and number of awakenings that correspond to 
like measures taken from various available self-report instruments (e.g., sleep diaries, PSQI, 
etc.) (Buysse et al., 2006). However, PSG also provides a number of measures that reflect the 
architecture of sleep such as the percentage or temporal amounts of stage 1 sleep, stage 2 
sleep, slow wave sleep or rapid eye movement (REM) sleep. Despite having no self-report 
analogues, these latter measures also have been employed by some as indices of sleep 
quality (Krystal & Edinger, 2008). 
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Most of the recent studies on quality of sleep use different questionnaires assessing various 
aspects of sleep. The Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, and the 
Berlin Questionnaire are most frequently applied. Results derived from these questionnaires 
are limited by the subjective perception/sincerity of the patients, and thus are an imperfect 
substitute for more objective research methods on sleep in patients with chronic uremia 
(Chen et al, 2006; Iliescu et al., 2003; Mollaoglu & Mollaoglu, 2009; Sabbatini et al., 2003). 
Researchers have documented that ESRD patients reported significantly poorer subjective 
quality of sleep in comparison to the general population (Holley et al., 1992; Parker, 2005). 
The reported prevalence of ‘poor sleep’, including sleep-wake complaints, sleep-disordered 
breathing and excessive sleepiness, in dialysis patients is in the range of 45–80% (Afshar et 
al., 2011; Parker, 1996; Walker et al., 1995; Wei et al., 2011 ). In a another study It was 
examined the quality of sleep in 89 subjects with ESRD on haemodialysis using the PSQI 
and found a prevalence of ‘poor sleep’ (global PSQI>5) of 71% (Iliescu et al., 2003). Also, 
decreased quality of sleep is common in dialysis patients and is associated with decreased 
health-related quality of life (Iliescu et al., 2003; Williams et al., 2002). 
 The complex evaluation of sleep in patients with renal disease may be accomplished only 
by means of polysomnography. Polysomnography includes the comprehensive evaluation 
of the patient during sleep by electroencephalography, electrooculography, myography, 
quantification of respiratory efforts (by plethysmography), pulseoxymetry and noninvasive 
evaluation of CO2 blood level, and heart rate measuring (Tatomir et al., 2007).  Parker et al. 
(2003) examined by polysomnography 16 patients with HD and 8 patients with pre-dialysis 
CKD. Dialysis patients, in comparison with non-dialyzed CKD subjects, have a shorter sleep 
time. The REM phase is also shortened, time until falling asleep is longer, and respiratory 
events are more frequent. The sleep latency period was double in renal patients without 
dialysis compared to those with dialysis. Moreover, the prevalence and severity of 
periodical limb movement is higher in dialysis patients, as well as the number of short-term 
awakening periods (Parker et al., 2003). The authors suggest that sleep disturbances may 
have a different etiology in dialyzed patients compared to pre-dialysis CKD subjects. 
Functional and psychological factors may play a more prominent role in the pre-dialysis 
group, whereas intrinsic sleep disruption (arousals, apneas and limb movements) secondary 
to intermittent daytime HD sessions may play a more prominent role in patients with 
chronic uremia. Taken as a whole, renal patients experience a significant reduction in sleep 
length and efficiency compared to the general population (Parker et al., 2005). 
The studies have shown poor the quality of sleep in HD patients to be associated with 
female sex, older age, caffeine intake, recombinant erythropoietin therapy, pain, 
cardiovascular disease, physical functioning, larger body mass index (BMI), exercise, 
dialysis adequacy, parathyroid hormone, serum creatinine and quality of life (QOL) (Benz et 
al., 1999; Sabatini et al., 2002; Walker et al., 1995). Hanly et al. (2003) examined daytime 
sleepiness with multiple sleep latency tests in 24 haemodialysis patients and found strong 
correlation between sleep latency and BUN. In addition, psychological problems do 
represent crucial factors in influencing the quality of sleep in hemodialysis patients, as 
emphasized by all the previous studies in prevalent patients with renal disease, with 
depression playing a prominent role, followed by anxiety, sexual problems, financial strains, 
and isolation (İliescu et al., 2003; İliescu et al., 2004; Markou et al.,2006; Novak et al.,2006).  
Considering the strict linkage between some of these factors affecting sleep and 
hemodialysis, it is tempting to speculate that treating sleep problems, while improving the 
overall quality of life, might positively affect hemodialysis. In addition, with this point of 
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view, psychological, behavioural and pharmacologic interventions that promote sleep will 
represent a more than promising area for future research in hemodialysis patients. 
The above  studies results show that the sleep characteristics of hemodialysis patients need 
to be routinely evaluated. In addition to medical treatment to eliminate the sleep problems 
of hemodialysis patients and increase their sleep quality, the implementation of sleep 
hygiene interventions that can play a part in the regularity of patients’ sleep could also be 
beneficial. These interventions would include an environment with a comfortable room 
temperature and ventilation, minimal noise, a comfortable bed, and proper lighting. These 
interventions should apply to each patient’s personal routines (Mollaoglu & Mollaoglu, 
2009). 
5. Management of sleep problems in hemodialysis patients 
Proper management of sleep problems in ESRD patients requires in the first instance a 
proper identification of sleep abnormalities (extensively discussed above). Although 
significant research has been done to characterize sleep abnormalities in hemodialysis 
patients (Holey et al., 1992; De Santo et al., 2005; Merlino et al., 2006), little has been 
published regarding proper treatment. In the absence of guidelines, nephrologists rely 
largely on some published data and on opinion-based medicine. Sleep problems lower 
quality of life and contribute to physical and mental health problems. Sleep disorders and 
lack of sleep are an under treated threat to the public health. Sleep professionals have 
recognized the behavioral components of sleep disorders for decades, yet most patients 
never get a proper diagnosis and treatment (Mollaoglu & Mollaoğlu, 2009). 
Periodic clinical assessment of sleep complaints should become routine for dialysis staff. 
Early identification of sleep problems and interventions to improve sleep quality is essential, 
because sleep disturbance that persists for a long period of time could decrease general 
health and functioning (Sabbatini et al., 2003; Tatomir et al., 2007). Increasing evidence 
supports the effectiveness of both pharmacologic and nonpharmacologic therapies for sleep 
problems (Edinger et al., 2001; Montgomery & Dennis, 2004; Smith et al., 2002).  
Pharmacologic therapy are discussed in the sleep disorders section. 
The most effective nonpharmacologic interventions tested to date include all or most of the 
following components: sleep hygiene instruction, sleep restriction, stimulus control, relaxation 
training, and cognitive modification (Edinger et al., 2001; Montgomery & Dennis, 2004).  
5.1 Sleep hygiene 
Sleep hygiene involves basic education on how the sleep environment, caffeine, alcohol, 
nicotine, food and exercise affect sleep (Smith et al., 2002). Sleep Hygiene is an educational 
approach designed to teach insomnia patients as well as the population at large how to 
maintain healthy behavioral habits which promote better sleep. It is important to 
understand that successful treatment is only possible if the patient complies with 
suggestions to improve sleep hygiene (Edinger et al., 2001). Below are summarized tips for 
sleep hygiene 
Sleep hygiene tips 
 Sleep only when sleepy. If you can't fall asleep within 20 min get up and do something 
boring until you feel sleepy, 
 Don't take nap sunless your doctor advises so. 
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 Regular sleep-wake schedule is important. Get up and go to bed the same time every 
day even on weekends. 
 Regular exercise improves sleep but most people should refrain from exercise at least 4 
hr before bedtime. 
 Develop sleep rituals (listening to musicetc.). It is important to give your body cues that 
it is time to slow down and sleep. 
 Only use your bed for sleeping and intimacy. Refrain from using your bed to watch TV 
or work. 
 Stay away from caffeine-containing beverages foods and medications nicotine and 
alcohol at least 4–6 hr before bedtime. 
 Have a light snack before bed with a glass of milk which contains sleep-promoting 
tryptophan. 
 Take a hot bath 90 min before bedtime. A hot bath will raise your body temperature but 
it is the drop in body temperature that may leave you feeling sleepy. 
 Make sure your bed and bedroom are quiet and comfortable. Use appropriate curtains 
ear plugs or a white noise machine if necessary. A cooler room is recommended. Use a 
humidifier if the air is too dry. 
These suggestions often combine several methods and may sound trivial. Compliance with 
such advice is still relatively poor however as it frequently requires changes in persistent 
“bad” habits which are ingrained (Morin et al., 1999). Building a regular sleep schedule and 
creating an appropriate sleeping environment as well as regular physical activity are very 
important in combating insomnia or insomnia-like presentations in RLS/PLMD 
(Montgomery & Dennis, 2004).  
In terms of sleep hygiene for RLS/PLMD, there are a two main points that bear 
highlighting. First, the avoidance of alcohol, caffeine and nicotine may be underscored 
because of their potential contribution to RLS symptoms and/or PLMs. Second, other sleep 
hygiene practices may or may not have any utility for patients with RLS. Particularly when 
sleep hygiene is provided to patients as a handout or pamphlet, there is no indication that 
this helps promote sleep in any patient group. (Martin, 2000; Pigeon &Yurcheshen, 2009). 
5.2 Relaxation and biofeedback techniques 
Relaxation and biofeedback techniques for treating insomnia are based on the assumption 
that insomnia patients are overly aroused and anxious, and this interferes with their ability 
to initiate and/or maintain sleep (Lacks, 1993). Relaxation techniques are designed simply to 
teach patients to relax, and thus improve their ability to sleep. Of several relaxation 
methods, none has been shown to be more efficacious than the others. Progressive muscle 
relaxation, autogenic training and electromyographic biofeedback seek to reduce somatic 
arousal (e.g., muscle tension), whereas attention-focusing procedures such as imagery 
training and meditation are intended to lower presleep cognitive arousal (e.g., intrusive 
thoughts, racing mind) (Spielman et al., 1987). 
 In general, biofeedback training is an effective treatment for some insomnia patients, and is 
as effective as other non-pharmacologic interventions (Morin et al., 1999). If patients can 
train themselves to relax before sleep or at night after an awakening, they are more capable 
or falling asleep and staying asleep. It is believed that the beneficial effects of these methods 
extend beyond the sleep problems in that they facilitate better coping skills in general 
(Martin, 2000). 
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Structured exercise programs may also improve symptoms of insomnia (Montgomery & 
Dennis., 2004). Despite the promise of CBT the relative efficacy of these various 
nonpharmacologic approaches has not been well established. Data also suggest that CBTin 
contrast to medications may have a lasting effect beyond the termination of treatment. The 
extent to which the concomitant use of nonpharmacologic therapy augments the performance 
of pharmacologic treatments needs to be established in further studies (Novak et al., 2006). 
5.3 Stimulus-control therapy 
Stimulus-control therapy is a behavioral approach based on the premise that some sleep 
disturbances are behaviorally conditioned, so that the patient associates the bedroom 
environment with arousal. The main objective of stimulus control therapy is to reassociate 
the bed and bedroom with the rapid onset of sleep. 
Below are summarized instructions for stimulus-control therapy (Martin, 2000).  
Instructions for Stimulus-Control Therapy 
 Patient goes to bed only when sleepy. 
 If not asleep within about 10 minutes, patient gets out of bed, and does not return to 
bed until sleepy. 
 When patient returns to bed, if not asleep within 15 minutes, gets out of bed. 
 Pattern is repeated until patient can fall asleep within a few minutes. 
 Must get up at the same time each morning (even if only slept 2 hours). 
 Bed is used only for sleeping (not for watching television, reading exciting books, etc). 
 All naps during the day must be avoided. 
This method focuses primarily on shortening sleep onset, however, in the case of sleep 
maintenance insomnia, the instructions may be followed when the patient awakens and 
cannot fall back to sleep during the night. The patient should avoid lying awake in bed as 
much as possible and only go to bed when sleepy. No stimulating or distracting activities 
(e.g. reading exciting books or articles, watching television, looking at a clock) should be 
available. Although the patient cannot control sleep onset, wake up time should be fixed, so 
that a regular sleep/wake schedule will develop. Pro hibiting daytime naps is important to 
take advantage of the sleep deficit accumulated since the sleep period on the previous night, 
which in itself can shorten sleep onset. As with all psychological therapies, compliance is 
enhanced when the instructions and their rationales are explained to the patient. 
Stimulus control therapy has been shown to be effective in shortening sleep latency 
compared with placebo intervention in insomnia patients (Lacks, Bertelson, Gans & Kunkel, 
1996). Clinical trials have documented the efficacy of stimulus control therapy for both sleep 
onset and sleep-maintenance insomnia (Espie et al., 1989; Lacks et al., 1993) 
5.4 Sleep restriction therapy 
Sleep restriction therapy, is based on the observation that many insomnia patients spend an 
excessive amount of time in bed in futile attempts to achieve more sleep (Spielman, Saskin, 
& Thorpy, 1987).. Sleep restriction therapy consists of curtailing the amount of time spent in 
bed to increase the percentage of time spent asleep. This improves the patient's sleep 
efficiency (time asleep/time in bed). For example, a person who reports staying in bed for 
eight hours but sleeping an average of five hours per night would initially be told to 
decrease the time spent in bed to five hours. The allowable time in bed per night is increased 
15 to 30 minutes as sleep efficiency improves. Adjustments are made over a period of weeks 
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until an optimal sleep duration is achieved. Typically, it is best to alter the bedtime and to 
keep the rising time constant in order to maintain a regular sleep-wake rhythm. By creating 
a mild state of sleep deprivation, this therapy promotes more rapid sleep onset and more 
efficient sleep (Hauri, 2000). To minimize daytime sleepiness, time in bed should not be 
reduced to less than five hours per night. Sleep restriction therapy is modified in older 
adults by allowing a short afternoon nap. 
Lichstein and Reidel (1994) concluded that sleep restriction therapy is actually the preferred 
technique for insomnia in older patients. In a later study they combined sleep restriction 
with sleep education for older insomnia patients, comparing a self-help technique (a guiding 
video) with therapist guidance (Riedel et al., 1995). While the self-help technique alone 
showed improvement on some sleep variables, therapist guidance was superior in that it 
improved sleep latency, wake time after sleep onset and sleep satisfaction. 
Implementation of this technique requires a high level of motivation and compliance on the 
patient’s part, and close follow up by the clinician. Below are listed the rules for sleep 
restriction therapy. 
Instructions for Sleep Restriction Therapy 
 Patient is only allowed to stay in bed for the amount of time they think they sleep each 
night, plus 15 minutes. For example, if patient reports sleeping only 5.75 hours, they are 
allowed to stayin bed for 6 hours. 
 Patient must get up at the same time each day. If normal waking time is 6:30, patient is 
allowed to go to bed at 12:30. 
 Napping is not allowed. 
 When sleep efficiency has reached 85%, the patient can go to bed 15 minutes earlier. 
 This procedure is repeated until the patient can sleep for the desired amount of time. 
5.5 Weight loss 
Upper-body obesity is a risk factor for OSA, and it is well documented that weight loss has a 
notable ameliorative impact on the occurrence of OSA (Ancoli-Israel et al., 1996; Smith et al., 
1985). Since OSA results from closure of the airway, excess fatty tissue in theneck area may 
be a contributing factor. This supports the notion that weight plays a significant role in the 
presence and severity of sleep disordered breathing although no conclusive treatment trials 
have been published at this time. 
5.6 Light therapy 
The most influential treatment for circadian rhythm disturbances is increased exposure to 
bright light. This form of therapy, which directly targets the circadian system, is much 
preferred over hypnotics and other sedative medications. Since light is the most important 
synchronizer in our circadian system, increasing bright light exposure during certain times 
of the day can shift circadian rhythm phase and increase its amplitude. Specifically, bright 
light exposure in the evening causes a phase delay, while morning bright light exposure 
causes a phase advance in circadian rhythms, including rhythms of melatonin, core body 
temperature and sleepiness (Martin et al., 2000). 
5.7 Cognitive-behavioral therapies 
Many behavioral sleep medicine interventions are based on cognitive-behavioral therapies 
(CBT). The focus is on systematically introducing behavioral changes that have been proven 
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to improve sleep. This could include changes in sleep schedule and changes in the 
contingencies and reinforcers that promote sleep. The cognitive approach focuses on looking 
internally to examine, manage, or modify sleep interfering thoughts and beliefs that can 
interfere with sleep. Cognitive behavioral therapy for insomnia in the routine general 
practice setting improved sleep quality reduced hypnotic drug use and improved health-
related quality of life at a favorable cost in chronic insomniacs. Randomized controlled trials 
(RCTs) report somewhat conflicting results on the effectiveness of CBT in patients with 
insomnia but one systematic review including six RCTs (282 people) found that group or 
individual cognitive behavioral therapy (including sleep hygiene stimulus control sleep 
restriction muscle relaxation and sleep education) significantly improved PSQI scores 
compared with no treatment immediately after treatment and at 3 months (Montgomery 
&Dennis, 2004). Furthermore another meta-analysis involving 2102 patients in 59 trials 
found that sleep restriction and stimulus control therapies were more effective than 
relaxation techniques when used alone (Edinger & Sampson., 2003).   
6. Conclusion 
Considering that the most frequent sleep complaints, such as insomnia, OSAS and RLS, are 
related to a significant negative impact on functional health status in uraemic patients, the 
nephrologists should improve their recognition and treatment of these conditions to restore 
the quality of life of their patients. A good sleep history and, when indicated, a sleep 
recording, will help the clinician to make an accurate diagnosis and thus identify the best 
treatment. Nonpharmacologic methods such as behavioral techniques and cognitive 
therapyas well as pharmacologic approaches and combinations of these methods should be 
used for the treatment of sleep problems in hemodialysis patients. 
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